CA2870271C - Fret-based lactate nanosensor comprising bacterial lldr for quantification of lactate and methods for quantifying metabolic rates and lactate transport - Google Patents
Fret-based lactate nanosensor comprising bacterial lldr for quantification of lactate and methods for quantifying metabolic rates and lactate transport Download PDFInfo
- Publication number
- CA2870271C CA2870271C CA2870271A CA2870271A CA2870271C CA 2870271 C CA2870271 C CA 2870271C CA 2870271 A CA2870271 A CA 2870271A CA 2870271 A CA2870271 A CA 2870271A CA 2870271 C CA2870271 C CA 2870271C
- Authority
- CA
- Canada
- Prior art keywords
- lactate
- seq
- cells
- nanosensor
- rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 title claims abstract description 312
- 238000000034 method Methods 0.000 title claims abstract description 96
- 102000000562 Monocarboxylic Acid Transporters Human genes 0.000 title claims abstract description 39
- 108010041817 Monocarboxylic Acid Transporters Proteins 0.000 title claims abstract description 39
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 20
- 238000011002 quantification Methods 0.000 title claims description 13
- 230000037323 metabolic rate Effects 0.000 title description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 62
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims abstract description 55
- 230000003834 intracellular effect Effects 0.000 claims abstract description 38
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 36
- 108091006047 fluorescent proteins Proteins 0.000 claims abstract description 19
- 102000034287 fluorescent proteins Human genes 0.000 claims abstract description 19
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 14
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 178
- 210000001519 tissue Anatomy 0.000 claims description 55
- 238000004113 cell culture Methods 0.000 claims description 33
- 238000005259 measurement Methods 0.000 claims description 32
- 238000001327 Förster resonance energy transfer Methods 0.000 claims description 27
- 108010082025 cyan fluorescent protein Proteins 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 21
- 238000009825 accumulation Methods 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 19
- 230000001464 adherent effect Effects 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 16
- 108091005957 yellow fluorescent proteins Proteins 0.000 claims description 13
- 210000003470 mitochondria Anatomy 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 11
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 claims description 10
- 241000545067 Venus Species 0.000 claims description 10
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 8
- 102000017298 Monocarboxylate transporters Human genes 0.000 claims description 8
- 108050005244 Monocarboxylate transporters Proteins 0.000 claims description 8
- 239000005090 green fluorescent protein Substances 0.000 claims description 8
- 108091005948 blue fluorescent proteins Proteins 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 239000011035 citrine Substances 0.000 claims description 3
- 229940126127 monocarboxylate transporter inhibitor Drugs 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 abstract description 24
- 206010028980 Neoplasm Diseases 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 18
- 201000011510 cancer Diseases 0.000 abstract description 17
- 230000002123 temporal effect Effects 0.000 abstract description 13
- 230000001413 cellular effect Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 230000019522 cellular metabolic process Effects 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 230000009466 transformation Effects 0.000 abstract description 4
- 206010021143 Hypoxia Diseases 0.000 abstract description 3
- 208000028867 ischemia Diseases 0.000 abstract description 3
- 230000037149 energy metabolism Effects 0.000 abstract description 2
- 230000007954 hypoxia Effects 0.000 abstract description 2
- 230000001575 pathological effect Effects 0.000 abstract description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 22
- 210000001130 astrocyte Anatomy 0.000 description 19
- 230000008859 change Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 12
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 11
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 11
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 11
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 230000006677 mitochondrial metabolism Effects 0.000 description 10
- 230000006682 Warburg effect Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 230000004907 flux Effects 0.000 description 8
- 230000002414 glycolytic effect Effects 0.000 description 8
- 230000010627 oxidative phosphorylation Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 7
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 7
- 102200082402 rs751610198 Human genes 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 208000032612 Glial tumor Diseases 0.000 description 5
- 206010018338 Glioma Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 108010092494 Periplasmic binding proteins Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000295 emission spectrum Methods 0.000 description 4
- 238000001506 fluorescence spectroscopy Methods 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000002407 ATP formation Effects 0.000 description 3
- 241000186226 Corynebacterium glutamicum Species 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000013178 mathematical model Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108091005960 Citrine Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000010198 maturation time Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000019261 negative regulation of glycolysis Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000004108 pentose phosphate pathway Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 102000015982 Pannexin Human genes 0.000 description 1
- 108050004251 Pannexin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 241000775914 Valdivia <angiosperm> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 230000006692 glycolytic flux Effects 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 230000037447 lactate metabolism Effects 0.000 description 1
- 150000003893 lactate salts Chemical group 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003702 neurovascular coupling effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/033639 WO2013154587A1 (en) | 2012-04-13 | 2012-04-13 | Genetically encoded probe for quantification of lactate, and methods for quantifying metabolic rates and lactate transport |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2870271A1 CA2870271A1 (en) | 2013-10-17 |
| CA2870271C true CA2870271C (en) | 2020-06-30 |
Family
ID=49327999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2870271A Expired - Fee Related CA2870271C (en) | 2012-04-13 | 2012-04-13 | Fret-based lactate nanosensor comprising bacterial lldr for quantification of lactate and methods for quantifying metabolic rates and lactate transport |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10466233B2 (enExample) |
| EP (1) | EP2836503B1 (enExample) |
| JP (1) | JP6106264B2 (enExample) |
| CA (1) | CA2870271C (enExample) |
| DK (1) | DK2836503T3 (enExample) |
| ES (1) | ES2602321T3 (enExample) |
| WO (1) | WO2013154587A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015025192A1 (en) * | 2013-08-20 | 2015-02-26 | Centro De Estudios Cientificos De Valdivia | Genetically encoded probe for quantification of pyruvate concentration and methods of using the same |
| DE102015115640B4 (de) * | 2015-09-16 | 2017-06-29 | Stiftung Caesar Center Of Advanced European Studies And Research | Verfahren zum Nachweis von Liganden vermittels Biosensoren |
| EP3377897B1 (en) * | 2015-11-20 | 2024-05-01 | Duke University | Lactate biosensors and uses thereof |
| EP3377904B1 (en) | 2015-11-20 | 2024-05-01 | Duke University | Urea biosensors and uses thereof |
| US20180371643A1 (en) * | 2015-11-30 | 2018-12-27 | Council Of Scientific & Industrial Research | Method of Identification of Combinatorial Enzymatic Reaction Targets in Glioblastoma Specific Metabolic Network |
| WO2018152480A1 (en) * | 2017-02-20 | 2018-08-23 | Richard Postrel | Method for precise identification, targeting and delivery of directed therapies for destruction of cancerous cells |
| US11175281B2 (en) | 2018-08-21 | 2021-11-16 | International Business Machines Corporation | Well plate cover with embedded electronic sensors for monitoring cell metabolism |
| KR102167605B1 (ko) * | 2019-05-20 | 2020-10-19 | 울산과학기술원 | 슈도모나스 플루오레센스 유래 신규 D-LldR 전사조절인자 기반의 D(-)-젖산 검출용 바이오 센서 |
| WO2021033015A1 (en) * | 2019-08-22 | 2021-02-25 | Centro De Estudios Científicos De Valdivia | Genetically encoded probe for detection and quantification of lactate/pyruvate ratio with high spatial and temporal resolution |
| CN113004420B (zh) * | 2019-12-19 | 2023-02-24 | 华东理工大学 | 乳酸光学探针及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3829252B2 (ja) * | 2001-06-08 | 2006-10-04 | 独立行政法人理化学研究所 | 蛍光蛋白質 |
| CA2457059A1 (en) | 2001-08-10 | 2003-02-20 | Ahram Biosystems Inc. | System for detecting protease |
| WO2003025220A2 (en) * | 2001-09-18 | 2003-03-27 | Carnegie Institution Of Washington | Fusion proteins useful for detecting analytes |
| AU2005295656B2 (en) * | 2004-10-14 | 2011-08-04 | Carnegie Institution Of Washington | Development of sensitive FRET sensors and methods of using the same |
| CA2599852A1 (en) * | 2005-03-04 | 2006-09-14 | Carnegie Institution Of Washington | Environmentally stable sensors and methods of using the same |
| US7790868B2 (en) * | 2005-05-20 | 2010-09-07 | The Governors Of The University Of Alberta | Teal fluorescent proteins (mTFP1) |
| US8173863B2 (en) * | 2005-10-14 | 2012-05-08 | Carnegie Institution Of Washington | Sucrose biosensors and methods of using the same |
-
2012
- 2012-04-13 CA CA2870271A patent/CA2870271C/en not_active Expired - Fee Related
- 2012-04-13 JP JP2015505696A patent/JP6106264B2/ja not_active Expired - Fee Related
- 2012-04-13 DK DK12874169.1T patent/DK2836503T3/en active
- 2012-04-13 US US14/394,018 patent/US10466233B2/en not_active Expired - Fee Related
- 2012-04-13 EP EP12874169.1A patent/EP2836503B1/en not_active Not-in-force
- 2012-04-13 WO PCT/US2012/033639 patent/WO2013154587A1/en not_active Ceased
- 2012-04-13 ES ES12874169.1T patent/ES2602321T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015512935A (ja) | 2015-04-30 |
| EP2836503A1 (en) | 2015-02-18 |
| WO2013154587A1 (en) | 2013-10-17 |
| EP2836503B1 (en) | 2016-06-08 |
| EP2836503A4 (en) | 2015-03-25 |
| DK2836503T3 (en) | 2016-09-19 |
| JP6106264B2 (ja) | 2017-03-29 |
| ES2602321T3 (es) | 2017-02-20 |
| US20150072375A1 (en) | 2015-03-12 |
| US10466233B2 (en) | 2019-11-05 |
| CA2870271A1 (en) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2870271C (en) | Fret-based lactate nanosensor comprising bacterial lldr for quantification of lactate and methods for quantifying metabolic rates and lactate transport | |
| San Martín et al. | A genetically encoded FRET lactate sensor and its use to detect the Warburg effect in single cancer cells | |
| Blay et al. | High-throughput screening: today’s biochemical and cell-based approaches | |
| Matlashov et al. | Fluorescent ratiometric pH indicator SypHer2: applications in neuroscience and regenerative biology | |
| Serber et al. | In-cell NMR spectroscopy | |
| Gest et al. | Molecular spies in action: Genetically encoded fluorescent biosensors light up cellular signals | |
| Bermejo et al. | Optical sensors for measuring dynamic changes of cytosolic metabolite levels in yeast | |
| Mohsin et al. | Genetically-encoded nanosensor for quantitative monitoring of methionine in bacterial and yeast cells | |
| Bilan et al. | Genetically encoded probes for NAD+/NADH monitoring | |
| De Michele et al. | Mitochondrial biosensors | |
| Zhao et al. | Profiling metabolic states with genetically encoded fluorescent biosensors for NADH | |
| Sharma et al. | Peptide-based fluorescent sensors of protein kinase activity: design and applications | |
| Manzoor et al. | Visualization of thiamine in living cells using genetically encoded fluorescent nanosensor | |
| EP3036528B1 (en) | Genetically encoded probe for quantification of pyruvate concentration and methods of using the same | |
| CN108519484A (zh) | 利用自连接标签的双分子荧光互补技术成像和追踪活细胞内的蛋白质相互作用 | |
| Pelosse et al. | Genetically encoded fluorescent biosensors to explore AMPK signaling and energy metabolism | |
| Zhang et al. | A multifunctional fluorescent probe for tracking SO2 fluctuation between mitochondria and endoplasmic reticulum in living cells and zebrafish | |
| Yang et al. | Collaborative light-off and light-on bacterial luciferase biosensors: Innovative approach for rapid contaminant detection | |
| Vaasa et al. | Small-molecule FRET probes for protein kinase activity monitoring in living cells | |
| JP2010535531A (ja) | Ｒｅｔナノセンサーの使用方法 | |
| WO2005093103A2 (en) | Development and use of fluorescent probes of unbound analytes | |
| Imai et al. | High-performance genetically-encoded green and red fluorescent biosensors for pyruvate | |
| WO2009009908A1 (en) | A recombmase based screening method for detecting molecular interactions comprising a single plasmid vector with two unique recombmase sites | |
| Nasu et al. | Improved genetically encoded fluorescent biosensors for monitoring of intra-and extracellular L-lactate | |
| US20220169682A1 (en) | Split photoactive yellow protein complementation system and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141010 |
|
| EEER | Examination request |
Effective date: 20141010 |
|
| MKLA | Lapsed |
Effective date: 20220413 |